Associate Professor, Pathology, UCSF School of Medicine
Pathology
Dr. Jeffry P. Simko, MD
|
|
Give Review
Jeffry P. Simko is an expert in the field of Pathology. He went to University of North Carolina at Chapel Hill School of Medicine. University of North Carolina at Chapel Hill School of Medicine is a top medical university. University of North Carolina at Chapel Hill School of Medicine is ranked 22/2 in Research/PrimaryCare. Jeffry Simko is also published. He has 36 publications published. The lastest publication: "Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens.' Doctor Jeffry P. Simko, MD accepts all Medicare patients.
Publications
- Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer.
- A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer.
- Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy.
- Extended Follow-Up and Risk Factors for Disease Reclassification from a Large Active Surveillance Cohort for Localized Prostate Cancer.
- Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor.
- A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling.
- Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: Quantitative analysis of imaging contour...
- Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy.
- Clinical utility of endorectal MRI-guided prostate biopsy: Preliminary experience.
- Semiautomatic registration of digital histopathology images to in vivo MR images in molded and unmolded prostates.
- Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
- Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3.
- Benign Prostate Glandular Tissue at Radical Prostatectomy Surgical Margins.
- Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort.
- Inhibition of Granzyme B by PI-9 protects prostate cancer cells from apoptosis.
- Do Adenocarcinomas of the Prostate With Gleason Score (GS)≤6 Have the Potential to Metastasize to Lymph Nodes?
- Measurements of T(1) -relaxation in ex vivo prostate tissue at 132 μT.
- Metastatic melanoma with striking adenocarcinomatous differentiation illustrating phenotypic plasticity in melanoma.
- Mucinous adenocarcinoma of the prostate: MRI and MR spectroscopy features.
- Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues.
- Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy.
- Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging.
- High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience.
- Prostate cancer: endorectal MR imaging and MR spectroscopic imaging--distinction of true-positive results from chance-detected lesions.
- Differences in laboratory findings for cerebrospinal fluid specimens obtained from patients with meningitis or encephalitis due to herpes simplex virus (HSV) documente...
- A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer.
- Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer.
- Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients.
- Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer.
- Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy.
- Molecular analysis of WFDC1/ps20 gene in prostate cancer.
- Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qt...
- Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy.
- Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens.
- Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.
Schools
University of North Carolina At Chapel Hill
Brigham and Women39s Hospital
Doctors Specialties
- Molecular Genetic Pathology
- Pathology
Accepted Insurances
- Blue Card PPO
- Advantage Preferred DirectAccess Plus PPO
- Brown & Toland Physicians
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Delta Health System
- Humana
- Medicare MCR
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
UCSF -
University of North Carolina at Chapel Hill School of Medicine
Hospital
-
San Francisco General Hospital and Trauma Center -
UCSF Medical Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225095748 |
| Last Name Of The Provider | SIMKO |
| First Name Of The Provider | JEFFRY |
| View All |
Similar Doctors
|
|
Dr. Arie Perry, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rosa S. Rosen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amy P. Hart, MD
This Doctor is OpenDoctor Recommended.
|